

# Martine Piccart

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1949466/publications.pdf>

Version: 2024-02-01

105  
papers

18,080  
citations

61857

43  
h-index

29081

104  
g-index

106  
all docs

106  
docs citations

106  
times ranked

19639  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. <i>Lancet, The</i> , 2014, 384, 164-172.	6.3	3,224
2	Everolimus in Postmenopausal Hormone-Receptorâ€“Positive Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 520-529.	13.9	2,474
3	Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis. <i>Journal of the National Cancer Institute</i> , 2006, 98, 262-272.	3.0	1,824
4	70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 717-729.	13.9	1,427
5	Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2017, 377, 122-131.	13.9	1,033
6	Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. <i>Breast Cancer Research</i> , 2008, 10, R65.	2.2	765
7	Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes. <i>Clinical Cancer Research</i> , 2008, 14, 5158-5165.	3.2	745
8	Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptorâ€“Positive, Advanced Breast Cancer: Results From EFACT. <i>Journal of Clinical Oncology</i> , 2008, 26, 1664-1670.	0.8	460
9	Clinical management of breast cancer heterogeneity. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 381-394.	12.5	400
10	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. <i>Annals of Oncology</i> , 2021, 32, 1216-1235.	0.6	354
11	An update on PARP inhibitorsâ€“moving to the adjuvant setting. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 27-41.	12.5	316
12	Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives. <i>Journal of Clinical Oncology</i> , 2014, 32, 2794-2803.	0.8	298
13	Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology, The</i> , 2016, 17, 811-821.	5.1	239
14	Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 540-551.	4.3	222
15	Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Advanced Breast Cancer: Results From BOLERO-2. <i>Journal of Clinical Oncology</i> , 2016, 34, 419-426.	0.8	203
16	Gene Modules and Response to Neoadjuvant Chemotherapy in Breast Cancer Subtypes: A Pooled Analysis. <i>Journal of Clinical Oncology</i> , 2012, 30, 1996-2004.	0.8	194
17	Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome. <i>Cell Reports</i> , 2015, 13, 277-289.	2.9	179
18	70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. <i>Lancet Oncology, The</i> , 2021, 22, 476-488.	5.1	179

#	ARTICLE	IF	CITATIONS
19	Progress in adjuvant systemic therapy for breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 27-44.	12.5	175
20	Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. <i>Journal of Clinical Oncology</i> , 2021, 39, 1448-1457.	0.8	171
21	Emerging targeted agents in metastatic breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 191-210.	12.5	158
22	The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics. <i>European Journal of Cancer</i> , 2008, 44, 84-91.	1.3	145
23	<sup>18</sup> F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1862-1868.	2.8	132
24	Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations. <i>Nature Communications</i> , 2017, 8, 14944.	5.8	126
25	RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy. <i>JAMA Oncology</i> , 2017, 3, 227.	3.4	118
26	HER2-Low Breast Cancer: Molecular Characteristics and Prognosis. <i>Cancers</i> , 2021, 13, 2824.	1.7	117
27	TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2011, 12, 527-539.	5.1	116
28	Endocrine treatment in breast cancer: Cure, resistance and beyond. <i>Cancer Treatment Reviews</i> , 2016, 50, 68-81.	3.4	114
29	Treatment of advanced HER2-positive breast cancer: 2018 and beyond. <i>Cancer Treatment Reviews</i> , 2018, 67, 10-20.	3.4	107
30	Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 127-138.	5.1	91
31	The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data. <i>Clinical Cancer Research</i> , 2017, 23, 2702-2712.	3.2	82
32	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. <i>Cancer Discovery</i> , 2021, 11, 2796-2811.	7.7	79
33	Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2019, 111, 86-94.	3.0	73
34	Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial. <i>Clinical Cancer Research</i> , 2019, 25, 3581-3588.	3.2	73
35	Uncovering the genomic heterogeneity of multifocal breast cancer. <i>Journal of Pathology</i> , 2015, 236, 457-466.	2.1	72
36	Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review. <i>Current Treatment Options in Oncology</i> , 2019, 20, 37.	1.3	60

#	ARTICLE	IF	CITATIONS
37	Biology of breast cancer during pregnancy using genomic profiling. <i>Endocrine-Related Cancer</i> , 2014, 21, 545-554.	1.6	58
38	Neoadjuvant Therapy for Breast Cancer. <i>Annual Review of Medicine</i> , 2015, 66, 31-48.	5.0	55
39	PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer?. <i>Npj Breast Cancer</i> , 2019, 5, 1.	2.3	55
40	Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06). <i>Breast Cancer Research and Treatment</i> , 2018, 168, 631-638.	1.1	49
41	Potential Benefit of Intra-operative Administration of Ketorolac on Breast Cancer Recurrence According to the Patient's Body Mass Index. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1115-1122.	3.0	49
42	The Role of Taxanes in the Adjuvant Treatment of Early Stage Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2003, 79, 25-34.	1.1	47
43	Characterization and Clinical Evaluation of CD10+ Stroma Cells in the Breast Cancer Microenvironment. <i>Clinical Cancer Research</i> , 2012, 18, 1004-1014.	3.2	46
44	Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells. <i>Nature Communications</i> , 2020, 11, 6335.	5.8	46
45	Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer. <i>BMC Medicine</i> , 2015, 13, 177.	2.3	45
46	Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 2605-2615.	3.2	45
47	Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial. <i>European Journal of Cancer</i> , 2016, 63, 97-104.	1.3	44
48	Drugs prescribed for patients hospitalized in a geriatric oncology unit: Potentially inappropriate medications and impact of a clinical pharmacist. <i>Journal of Geriatric Oncology</i> , 2016, 7, 463-470.	0.5	43
49	Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial. <i>Clinical Cancer Research</i> , 2019, 25, 3887-3895.	3.2	42
50	Circumventing De Novo and Acquired Resistance to Trastuzumab: New Hope for the Care of ErbB2-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2008, 8, S100-S113.	1.1	37
51	HER-2 as a Target for Breast Cancer Therapy. <i>Clinical Cancer Research</i> , 2009, 15, 1848-1852.	3.2	36
52	Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer. <i>European Journal of Cancer</i> , 2020, 125, 69-82.	1.3	36
53	Recurrence dynamics of breast cancer according to baseline body mass index. <i>European Journal of Cancer</i> , 2017, 87, 10-20.	1.3	35
54	Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 103-114.	1.1	34

#	ARTICLE	IF	CITATIONS
55	Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1386.	1.8	33
56	Final 10-year results of the Breast International Group 2008 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. <i>European Journal of Cancer</i> , 2015, 51, 1481-1489.	1.3	32
57	Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. <i>Breast</i> , 2021, 59, 327-338.	0.9	31
58	Is the differentiation into molecular subtypes of breast cancer important for staging, local and systemic therapy, and follow up?. <i>Cancer Treatment Reviews</i> , 2014, 40, 1089-1095.	3.4	30
59	Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFFECT). <i>European Journal of Cancer</i> , 2019, 114, 55-66.	1.3	30
60	A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378). <i>European Journal of Cancer</i> , 2016, 53, 144-154.	1.3	29
61	Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1335-1345.	0.8	28
62	Personalized therapy for breast cancer: a dream or a reality?. <i>Future Oncology</i> , 2013, 9, 1105-1119.	1.1	27
63	What Is the Real Impact of Estrogen Receptor Status on the Prognosis and Treatment of HER2-Positive Early Breast Cancer?. <i>Clinical Cancer Research</i> , 2020, 26, 2783-2788.	3.2	27
64	Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0154009.	1.1	27
65	Lapatinib-Related Rash and Breast Cancer Outcome in the ALTO Phase III Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw037.	3.0	24
66	Phylogenetic reconstruction of breast cancer reveals two routes of metastatic dissemination associated with distinct clinical outcome. <i>EBioMedicine</i> , 2020, 56, 102793.	2.7	22
67	The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence. <i>JAMA Oncology</i> , 2016, 2, 217.	3.4	21
68	Systemic treatment of patients with early breast cancer: recent updates and state of the art. <i>Breast</i> , 2019, 48, S7-S20.	0.9	21
69	Association between the histopathological growth patterns of liver metastases and survival after hepatic surgery in breast cancer patients. <i>Npj Breast Cancer</i> , 2020, 6, 64.	2.3	20
70	Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 462-470.	3.0	20
71	Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 199-209.	1.1	19
72	Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015. <i>Breast</i> , 2015, 24, S143-S148.	0.9	18

#	ARTICLE	IF	CITATIONS
73	The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer. PLoS ONE, 2015, 10, e0138341.	1.1	16
74	Beyond Trastuzumab and Lapatinib: New Options for HER2-Positive Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e2-e11.	1.8	16
75	New anticancer agents and therapeutic strategies in development for solid cancers: a clinical perspective. Expert Review of Anticancer Therapy, 2004, 4, 53-60.	1.1	15
76	New Strategies in Breast Cancer: The Significance of Molecular Subtypes in Systemic Adjuvant Treatment for Small T1a,bN0M0 Tumors. Clinical Cancer Research, 2014, 20, 6242-6246.	3.2	15
77	Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge. Cancer Treatment Reviews, 2021, 99, 102229.	3.4	15
78	Endocrine therapy and palbociclib within a compassionate use program in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer. Breast, 2018, 39, 14-18.	0.9	14
79	Use of trastuzumab for the treatment of early stage breast cancer. Expert Review of Anticancer Therapy, 2006, 6, 1153-1164.	1.1	13
80	An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: The trastuzumab case. European Journal of Cancer, 2014, 50, 3089-3097.	1.3	13
81	First-Line Treatment of Metastatic Breast Cancer. American Journal of Cancer, 2006, 5, 99-110.	0.4	11
82	Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study. BMC Cancer, 2013, 13, 190.	1.1	11
83	Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: A retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy. Breast, 2014, 23, 473-481.	0.9	11
84	Targeted adjuvant therapy in breast cancer. Expert Review of Anticancer Therapy, 2016, 16, 1263-1275.	1.1	11
85	Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial. Journal of Clinical Oncology, 2020, 38, 1186-1197.	0.8	10
86	Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA. PLoS ONE, 2017, 12, e0172351.	1.1	10
87	The AURORA pilot study for molecular screening of patients with advanced breast cancer—a study of the breast international group. Npj Breast Cancer, 2017, 3, 23.	2.3	8
88	Tumor dormancy at bedside: A late awakening. Breast, 2019, 45, 61-63.	0.9	8
89	Late effects of adjuvant chemotherapy adumbrate dormancy complexity in breast cancer. Breast, 2020, 52, 64-70.	0.9	8
90	Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. European Journal of Cancer, 2022, 164, 39-51.	1.3	8

#	ARTICLE	IF	CITATIONS
91	Novel therapeutics in breast cancer – Looking to the future. Update on Cancer Therapeutics, 2009, 3, 189-205.	0.9	7
92	Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience. Breast Cancer Research and Treatment, 2016, 155, 127-132.	1.1	7
93	Controlling technical variation amongst 6693 patient microarrays of the randomized MINDACT trial. Communications Biology, 2020, 3, 397.	2.0	7
94	Trastuzumab and Breast Cancer. Are we just Beyond the Prologue of a Fascinating Story?. Oncology Research and Treatment, 2005, 28, 547-549.	0.8	6
95	Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial. Clinical Cancer Research, 2021, 27, 5607-5618.	3.2	5
96	Charcot-Marie-Tooth hereditary neuropathy revealed after administration of docetaxel in advanced breast cancer. World Journal of Clinical Oncology, 2017, 8, 425-428.	0.9	5
97	Cancer drugs, survival and ethics: a critical look from the inside. ESMO Open, 2016, 1, esmoopen-2016-000149.	2.0	4
98	Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer. British Journal of Cancer, 2021, 125, 38-47.	2.9	4
99	Unusual presentation of nasopharyngeal carcinoma with rectal metastasis. World Journal of Clinical Cases, 2017, 5, 183.	0.3	4
100	Management of early breast cancer in patients bearing germline BRCA mutations. Seminars in Oncology, 2020, 47, 243-248.	0.8	3
101	Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy. Journal of the National Cancer Institute, 2022, 114, 1117-1126.	3.0	3
102	Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D). Breast Cancer Research and Treatment, 2021, 185, 107-116.	1.1	2
103	Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) Trial. Clinical Breast Cancer, 2022, 22, 308-318.	1.1	2
104	Abstract PS12-17: Baseline characteristics of women enrolled in the POSITIVE trial (pregnancy outcome) Tj ETQq0 0 0 rgBT /Qverlock 10		
105	Personalized medicine for breast cancer: dream or reality?. Memo - Magazine of European Medical Oncology, 2013, 6, 158-166.	0.3	0